“It should be observed that, in combination with cisplatin C ), docetaxel or gemcitabine (G), MTA presents synergistic efficacy: two phase II protocols have shown that the MTA/C combination as first-line therapy presented high efficacy (objective response: 39-45%) and low toxicity.”